RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Last Timebencro wrote: Bunge ... I, and most probably just like you, talked about this technology to many people (even doctors, health care professionals) and they don't really care. Like "that's not possible". Or "I heard it's not that efficient". Same story about drugs vs therapeutic lasers. Until they'll hear about real cases.
I told you to buy shares at 2$ and you'll see that market won't follow. For now ... ;-)
Because for now, markets simply doesn't believe in it ... now. And that's human nature. Same as for many other TSX-Venture stocks ... until you finally see them pop-up strong. Truth of the matter, it's the same company as the day before!
I could cite many. DYA is probably the next one. Check it out Monday morning after it resume. Despite many recent hints, some didn't want to believe in it. Then, a simple special guest at the AGM and suddently, everybody wants in now. Everybody is ready to pay a prime to get in. Still the same CEO that some were bashing on up to last week.
In the case of TLT, we all know human data will change all that. So whether we sit at 2$ now or 0.30$, it doesn't change anything if it's going to work because unless you want to sell before human data is out, it changes nothing. That's why your whining lacks credibility. Especially when we all know that we're ahead of the pack and ahead of big pharmas low efficient and unstable auto-immune blockbusters. All we need to do is to demonstrate efficacy on humans and let the market decide and react.
And when your brother-in-law, your neighbourgh, the tv news will make mention of PDT/PDC breakthrough and how efficient it is in destroying some cancers, you'll have to remember that this is the same management and same CEO than today.
Merck is currently adversizing its Keytruda on TV these days. We're already in a biotech that could be way more efficient to a point that it has all the ingredients to displace Merck, BMS and Roche's auto-immune blockbuster drugs markets in a blink. Costs, duration of treatment, higher potency, precision of treatment, low toxicity, predictability of treatment, larger pool of patients, etc .... Big Pharmas solution look pale in comparison to PDR/PDC, when you think of it. But very few are aware of the difference our tiny PDC molecule is about to make. So again, we only have to produce these human data.
https://www.stockhouse.com/companies/bullboard?symbol=v.dya&postid=26031820 hi.Bunge and Ben, I did some DD on Dya.v, and get a conclusion, Tlt's success would be even more epic than that of Dya.v. Maybe Tlt management should now consider of moving Tlt into Tsx as Dya just did, as Tlt has Fda approved products after all. See now the above link even started to compare Dya as pre-succes msft and aapl. May our glory days come earlier,